AVEYABEC Trademark

Trademark Overview


On Monday, April 20, 2020, a trademark application was filed for AVEYABEC with the United States Patent and Trademark Office. The USPTO has given the AVEYABEC trademark a serial number of 88879903. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, September 8, 2021. This trademark is owned by Celgene Corporation. The AVEYABEC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
aveyabec

General Information


Serial Number88879903
Word MarkAVEYABEC
Filing DateMonday, April 20, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, September 8, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 29, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Wednesday, September 8, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, September 8, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, January 26, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 26, 2021FINAL REFUSAL E-MAILED
Tuesday, January 26, 2021FINAL REFUSAL WRITTEN
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NON-FINAL ACTION WRITTEN
Saturday, July 11, 2020ASSIGNED TO EXAMINER
Wednesday, April 29, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 23, 2020NEW APPLICATION ENTERED IN TRAM